MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Pfizer Total Non Current Liabilities 2011-2026 | PFE
Annual Total Non Current Liabilities Pfizer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 66.7 B | 63.8 B | 69.7 B | 80.7 B | 73.1 B | 76 B | 72.1 B | 75.5 B | 77.3 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 80.7 B | 63.8 B | 72.8 B |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
383 M | $ 0.81 | -3.11 % | $ 37 M |  Israel |
 |
Exelixis
EXEL
|
63.6 M | $ 46.21 | -5.11 % | $ 12.5 B | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
83.9 M | $ 2.43 | -4.71 % | $ 67.8 M | USA |
 |
Heron Therapeutics
HRTX
|
14.6 M | $ 1.24 | -5.73 % | $ 207 M | USA |
 |
InflaRx N.V.
IFRX
|
678 K | $ 2.86 | 14.2 % | $ 192 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
1.28 B | $ 75.53 | -1.72 % | $ 12.1 B | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 92.4 | -3.0 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Kymera Therapeutics
KYMR
|
157 M | $ 85.56 | -0.81 % | $ 7.23 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
711 M | $ 212.11 | -8.79 % | $ 3.88 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 22.02 | 2.51 % | $ 3.65 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
50.3 M | $ 100.27 | -8.92 % | $ 5.03 B | USA |
 |
MannKind Corporation
MNKD
|
219 M | $ 3.59 | 0.7 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 3.15 | - | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.65 | 8.96 % | $ 6.01 M | Israel |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
915 K | $ 0.65 | -4.03 % | $ 3.56 M | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Nanobiotix S.A.
NBTX
|
44.5 M | $ 43.46 | 3.82 % | $ 286 B | France |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 21.33 | -11.75 % | $ 2.71 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Genmab A/S
GMAB
|
769 M | $ 27.16 | -2.62 % | $ 16.8 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |